Literature DB >> 20676867

Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.

Manuel Vial, Luis Grande, Manuel Pera.   

Abstract

The incidence of adenocarcinoma of the esophagus and esophagogastric junction (gastric cardia) has risen rapidly over the past three decades in the United States and northern Europe. This increase had been most dramatic among White males. The majority of these cancers arise from Barrett's esophagus. However, less than 10% of the patients with esophageal adenocarcinoma were known to have Barrett's esophagus before. Current evidence indicates that gastroesophageal reflux and obesity are major risk factors for adenocarcinoma of the esophagus. Abdominal obesity, more prevalent in males, and independent of body mass index, seems to be associated with an increased risk of esophageal adenocarcinoma but not of cardia adenocarcinoma. This observation may explain the high male:female ratio observed in esophageal adenocarcinoma. Tobacco use has also been found as a possible risk factor for adenocarcinoma of the esophagus and gastric cardia. Infection with Helicobacter pylori and the use of nonsteroidal anti-inflammatory drugs might reduce the risk. On the other hand, low intake of fruits, vegetables, and cereal fibers seem to increase the risk of esophageal adenocarcinoma. Currently, there is no evidence that strongly supports any specific strategy to screen a subgroup of the population at risk for adenocarcinoma of the esophagus or esophagogastric junction. Future strategies to decrease obesity and tobacco use might help to reduce the burden of esophageal adenocarcinoma at least partially.

Entities:  

Mesh:

Year:  2010        PMID: 20676867     DOI: 10.1007/978-3-540-70579-6_1

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  40 in total

1.  Identification of a 5-gene signature for clinical and prognostic prediction in gastric cancer patients upon microarray data.

Authors:  Zhigang Wang; Zhi Yan; Bicheng Zhang; Zhiguo Rao; Yafei Zhang; Jian Liu; Lifang Yu; Yong Zhao; Bo Yang; Tingting Wu; Jianfei Gao
Journal:  Med Oncol       Date:  2013-08-03       Impact factor: 3.064

2.  Esophageal adenocarcinoma presenting as pseudo-achalasia in a patient with juvenile polyposis syndrome: an enemy out of the blue.

Authors:  Carlene Lihalakha Chun; Saul Eisenstat; Shane Dormady; Charles Lombard; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-01-26       Impact factor: 3.199

3.  Laparoscopic-assisted versus open total gastrectomy for Siewert type II and III esophagogastric junction carcinoma: a propensity score-matched case-control study.

Authors:  Chang-Ming Huang; Chen-Bin Lv; Jian-Xian Lin; Qi-Yue Chen; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Long-Long Cao; Mi Lin; Ru-Hong Tu
Journal:  Surg Endosc       Date:  2016-12-15       Impact factor: 4.584

4.  Total esophagogastrectomy plus extended lymphadenectomy with transverse colon interposition: A treatment for extensive esophagogastric junction cancer.

Authors:  Marco Ceroni; Enrique Norero; Juan Pablo Henríquez; Eduardo Viñuela; Eduardo Briceño; Cristian Martínez; Gloria Aguayo; Fernando Araos; Paulina González; Alfonso Díaz; Mario Caracci
Journal:  World J Hepatol       Date:  2015-10-08

5.  Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.

Authors:  Surendra Pal Chaudhary; Eunice L Kwak; Jeffrey W Clark; Theodore S Hong; Katie L Hwang; Jochen K Lennerz; Ryan B Corcoran; Rebecca S Heist; Andrea L Russo; Aparna Parikh; Darrell R Borger; Lawrence S Blaszkowsky; Jason E Faris; Janet E Murphy; Christopher G Azzoli; Eric J Roeland; Lipika Goyal; Jill Allen; John T Mullen; David P Ryan; A John Iafrate; Samuel J Klempner
Journal:  Oncologist       Date:  2020-09-12

Review 6.  Carcinoma of the gastroesophageal junction in Chinese patients.

Authors:  Qin Huang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

7.  Targeting chemokine pathways in esophageal adenocarcinoma.

Authors:  Makardhwaj S Shrivastava; Zulfiqar Hussain; Orsolya Giricz; Niraj Shenoy; Rahul Polineni; Anirban Maitra; Amit Verma
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.

Authors:  Fausto Petrelli; Michele Ghidini; Sandro Barni; Giovanni Sgroi; Rodolfo Passalacqua; Gianluca Tomasello
Journal:  Gastric Cancer       Date:  2018-11-27       Impact factor: 7.370

9.  Esophageal cancer in Canada: trends according to morphology and anatomical location.

Authors:  Michael C Otterstatter; James D Brierley; Prithwish De; Larry F Ellison; Maureen Macintyre; Loraine D Marrett; Robert Semenciw; Hannah K Weir
Journal:  Can J Gastroenterol       Date:  2012-10       Impact factor: 3.522

10.  HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India.

Authors:  Mallika Tewari; Akhileshwar Kumar; R R Mishra; Mohan Kumar; Hari S Shukla
Journal:  Indian J Surg       Date:  2013-02-05       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.